CollPlant Ltd. (TASE:CLPT), a regenerative medicine company utilizing its proprietary plant-based rhCollagen technology for tissue repair products, today announced positive interim clinical trial results for Vergenix™STR, intended for the treatment of tendinopathy. The objective of the Company’s prospective, open label,

Share on LinkedInShare on FacebookShare on Google+Pin on PinterestEmail this to someone